Table 1 Clinical manifestations and laboratory data of DM patients, PM patients, and controls
From: The roles of neutrophil serine proteinases in idiopathic inflammatory myopathies
Clinical characteristic | NC (n = 39) | DM (n = 48) | PM (n = 16) | P valuea | ||
|---|---|---|---|---|---|---|
DM vs NC | PM vs NC | DM vs PM | ||||
Age, mean ± SD | 48.87 ± 12.40 | 50.25 ± 11.97 | 44.41 ± 11.99 | 0.606 | 0.2170 | 0.0889 |
Sex (male/female) | 9/30 | 11/37 | 6/10 | 0.986 | 0.275 | 0.253 |
Disease duration (months) | – | 15.41 ± 21.34 | 23.00 ± 34.25 | – | – | 0.3138 |
CK (U/L)b | – | 842.46 ± 1969.14 | 4368.46 ± 7149.77 | – | – | 0.061 |
LDH (U/L)c | – | 409.43 ± 267.63 | 612.02 ± 432.16 | – | – | 0.032* |
ESR (mm/h)d | – | 57.93 ± 95.67 | 43.29 ± 34.00 | – | – | 0.542 |
CRP (mg/L)e | – | 14.92 ± 20.72 | 12.99 ± 23.47 | – | – | 0.766 |
IgA (mg/L)f | – | 2625.22 ± 1408.36 | 2660.25 ± 1308.82 | – | – | 0.932 |
IgM (mg/L)g | – | 1848.37 ± 1546.84 | 1715.38 ± 874.10 | – | – | 0.748 |
IgG (g/L)h | – | 29.58 ± 98.34 | 16.70 ± 7.69 | – | – | 0.616 |
C3 (mg/l)u | – | 888.65 ± 238.43 | 967.25 ± 319.90 | – | – | 0.318 |
C4 (mg/l)j | – | 243.07 ± 127.62 | 299.75 ± 347.79 | – | – | 0.534 |
Jo-1 (positive/negative) | – | 11/37 | 5/11 | – | – | 0.505 |
Ro-52 (positive/negative) | – | 16/32 | 2/14 | – | – | 0.108 |
ILD (yes/no) | – | 23/23 | 3/13 | – | – | 0.029* |
Prednisone (yes/no) | – | 46/2 | 16/0 | – | – | 0.407 |
Cyclophosphamide (yes/no) | – | 6/42 | 1/15 | – | – | 0.488 |
Methotrexate (yes/no) | – | 8/40 | 5/11 | – | – | 0.209 |
Azathioprine (yes/no) | – | 9/39 | 5/11 | – | – | 0.295 |
Mycophenolate mofetil (yes/no) | – | 4/40 | 0/16 | – | – | 0.212 |
Thalidomide (yes/no) | – | 25/23 | 1/15 | – | – | 0.001* |
Hydroxychloroquine (yes/no) | – | 29/19 | 4/12 | – | – | 0.014* |
Total glucosides of Paeonia (yes/no) | – | 16/32 | 7/9 | – | – | 0.452 |